- BioPharm International-12-02-2006
- Volume 2006
- Issue 7
The Grand Alliances
The life sciences industry continues to move at an astonishing pace. Covering biotechnology, healthcare, pharmaceuticals, informatics, tools, instrumentation, and device companies, the sector draws from a vast, multidisciplinary array of technologies including optical, software, engineering, electronics, and nanotechnology.
The life sciences industry continues to move at an astonishing pace. Covering biotechnology, healthcare, pharmaceuticals, informatics, tools, instrumentation, and device companies, the sector draws from a vast, multidisciplinary array of technologies including optical, software, engineering, electronics, and nanotechnology.
Today, we are witnessing the rise of a relatively new breed of life science players—dubbed "convergence" companies—who combine this extraordinary diversity of skill sets with the commercial savvy required to turn science into real-world solutions. Such application of robust, proven technologies to find new solutions for new markets is creating a revolution across the world and is something at which Scotland excels.
David Gow of Touch Bionics, part of a new generation of commercially savvy convergence companies
Longer life expectancies in the developed world and a growing impetus to tackle threats to global health are driving a phenomenal acceleration in innovation and development among the life sciences community. It has been predicted that, within the year, biotechnology and healthcare products will account for 18% of GDP in the US.
This huge opportunity is already being seized by multinational companies such as 3Com (
For Scotland's part, innovation in the fields of opto- and micro-electronics, engineering, and software is now being exploited by a commercially savvy new generation of convergence businesses driving products into these key global markets. Companies such as Biopta (
ITI Techmedia (
Convergence companies, by the very nature of their business, are driven by collaboration and partnerships. Whether technical or commercial, the alliance of knowledge and expertise from different sectors and markets provides a compelling proposition.
An example of how this translates into business benefit is Voxar, the Edinburgh-based company founded in 1995 by Andrew Bissell to develop three-dimensional medical visualization software solutions for the clinical market. Voxar's success in forging strategic partnerships with many of the world's leading original equipment manufacturers played a key part in the eventual acquisition of the company by the Belgian company Barco (
Their agility, relatively rapid time to market, and reliance on proven technologies make convergence companies an attractive proposition to partners and investors alike. So, with Scotland's crop of homegrown talent knocking loudly on international doors, what is good for these companies is also good for our global standing and the advancement of medicine across the world.
Articles in this issue
almost 19 years ago
Stem Cell Industry Puts Scotland in the Spotlightalmost 19 years ago
The Next Generation: Scottish R&D in Life Sciencesalmost 19 years ago
The Talent Poolalmost 19 years ago
A Capable Communityalmost 19 years ago
Scotland: Ushering in the next age of life sciencesalmost 19 years ago
Centers of Excellencealmost 19 years ago
Revolutionizing Translational Medicine through CollaborationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.